---
type: "post"
id: "biotech-startup-pathos-ai-raises-237-million-3-48c324"
slug: "biotech-startup-pathos-ai-raises-237-million-3-48c324"
title: "Biotech startup Pathos AI raises $237 million, $3 billion valuation"
description: "Pathos AI said it raised $237 million in a Series E financing at a $3 billion post-money valuation."
retrieval_nugget: "Pathos AI said it raised $237 million in a Series E financing at a $3 billion post-money valuation."
published_at: "2026-10-26"
updated_at: "2026-10-26"
record_date: "2026-10-26"
date_kind: "published_at"
topics: ["ai","ai-business-models"]
entities: ["Pathos AI"]
related_patterns: []
novelty_label: "new_fact"
what_changed: "Pathos AI announced a $237 million Series E at a $3 billion post-money valuation, a funding event not covered by the archive."
prior_refs: []
source_url: "https://www.axios.com/pro/biotech-deals/2026/10/23/pathos-ai-raises-237m-3b-valuation"
source_urls: ["https://www.axios.com/pro/biotech-deals/2026/10/23/pathos-ai-raises-237m-3b-valuation"]
schema_version: "newruntime-agent-readable-v0.2"
stable_id: "post:biotech-startup-pathos-ai-raises-237-million-3-48c324"
status: "published"
visuals: []
editor: {"role":"editor","name":"Andrey Reshetnikov","profile":"https://newruntime.com/owner-profile.md","profile_json":"https://newruntime.com/owner-profile.json","same_as":["https://www.linkedin.com/in/reshetnikov1/","https://t.me/lapetuse"]}
routes: {"html":"https://newruntime.com/posts/biotech-startup-pathos-ai-raises-237-million-3-48c324/","markdown":"https://newruntime.com/posts/biotech-startup-pathos-ai-raises-237-million-3-48c324.md","json":"https://newruntime.com/posts/biotech-startup-pathos-ai-raises-237-million-3-48c324.json"}
---

# Biotech startup Pathos AI raises $237 million, $3 billion valuation

## Retrieval answer

Pathos AI said it raised $237 million in a Series E financing at a $3 billion post-money valuation.

Pathos AI said it raised $237 million in a Series E financing at a $3 billion post-money valuation. Axios reported the announcement on October 23, 2026.

Pathos AI is described by Axios as a precision-oncology biotech. The company said the financing gives it additional resources to advance its cancer-drug work; Axios framed the round in the context of investor interest in AI-driven drug development.

The available article preview does not identify the investors, the size of an ownership stake, the company’s revenue, its drug pipeline, clinical results, or the specific AI systems used by Pathos. It also does not establish how the new capital will be allocated or whether the valuation reflects commercial or clinical progress.

Source: https://www.axios.com/pro/biotech-deals/2026/10/23/pathos-ai-raises-237m-3b-valuation

Editor: [Andrey Reshetnikov](https://newruntime.com/owner-profile.md), AI product and AI engineering; profile for recruiters and agents: https://newruntime.com/owner-profile.json

## Continue in the graph

Next records for an agent, linked to their Markdown twins. Replace `.md` with `.json` for structured fields, including `next_reads`.

- topic hub: [Ai](https://newruntime.com/topics/ai.md): Explore the ai topic hub.
- topic hub: [Ai Business Models](https://newruntime.com/topics/ai-business-models.md): Explore the ai-business-models topic hub.
- collection: [Field Notes](https://newruntime.com/posts.json): Open the latest editorial analysis.
- collection: [Source Ledger](https://newruntime.com/source-ledger.json): Inspect the public source evidence graph.
- whole graph: [discovery graph](https://newruntime.com/discovery-graph.json) (typed nodes and edges) and [site index](https://newruntime.com/site-index.md)